NDLI: Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

Please wait, while we are loading the content...

Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Adherence to rotavirus vaccination quality measures in a commercially insured population.

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

An improved whole cell pertussis vaccine with reduced content of endotoxin.

Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.

A pilot study on the effects of individually tailored education for MMR vaccine-hesitant parents on MMR vaccination intention.

Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.

Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease.

Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.

Recommendations for tick-borne encephalitis vaccination from the Central European Vaccination Awareness Group (CEVAG).

A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Do the quality of the trials and the year of publication affect the efficacy of intervention to improve seasonal influenza vaccination among healthcare workers?: Results of a systematic review.

Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Autologous heat-shock protein vaccines.

Correlates of comfort with alternative settings for HPV vaccine delivery.

Phenotypic and functional analysis of the modification of murine bone marrow dendritic cells (BMDCs) induced by neutral Ginseng polysaccharides (NGP).

Bordetella pertussis infection in a child with completed primary immunization: A case report.

New generation of dendritic cell vaccines.

Development of a Vero cell DNA reference standard for residual DNA measurement in China.

Profile: transgene.

GSK's four-strain seasonal influenza vaccine approved in the US.

Letter from the editor.

Year: 2013 Volume: 9 Issue: 1

Year: 2012 Volume: 8

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Caoili, Salvador Eugenio C.
Description	Country affiliation: Philippines Author Affiliation: Caoili SE ( Department of Biochemistry and Molecular Biology)
Abstract	If new scientific knowledge is to be more efficiently generated and applied toward the advancement of health, human safety must be more effectively addressed in the conduct of research. Given the present difficulties of accurately predicting biological outcomes of novel interventions in vivo, the imperative of human safety suggests the development of novel pharmaceutical products in tandem with their prospective antidotes in anticipation of possible adverse events, to render the risks of initial clinical trials more acceptable from a regulatory standpoint. Antibody-mediated immunity provides a generally applicable mechanistic basis for developing antidotes to both biologicals and small-molecule drugs (such that antibodies may serve as antidotes to pharmaceutical agents as a class including other antibodies) and also for the control and prevention of both infectious and noninfectious diseases via passive or active immunization. Accordingly, the development of prophylactic or therapeutic passive-immunization strategies using antipeptide antibodies is a plausible prelude to the development of corresponding active-immunization strategies using peptide-based vaccines. In line with this scheme, global proliferation of antibody- and vaccine-production technologies, especially those that obviate dependence on the cold chain for storage and transport of finished products, could provide geographically distributed breakout capability against emerging and future health challenges.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
Journal	Human Vaccines & Immunotherapeutics
Issue Number	2
Volume Number	9
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-02-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Antibodies Isolation & Purification Pharmacology Antidotes Biological Products Antagonists & Inhibitors Immunization, Passive Clinical Trials As Topic Drug Discovery
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development

The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos.

Profile. DanDrit Biotech.

Hepatitis C vaccine. Need of the hour.

Dengue vaccine: come let's fight the menace.

Integrin-based therapeutics: biological basis, clinical use and new drugs.

Meningococcal group B vaccines.

Beyond new chemical entities: advancing drug development based on functional versatility of antibodies.

Alzheimer disease immunotherapeutics: then and now.

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

Similar Documents

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development

The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos.

Profile. DanDrit Biotech.

Hepatitis C vaccine. Need of the hour.

Dengue vaccine: come let's fight the menace.

Integrin-based therapeutics: biological basis, clinical use and new drugs.

Meningococcal group B vaccines.

Beyond new chemical entities: advancing drug development based on functional versatility of antibodies.

Alzheimer disease immunotherapeutics: then and now.

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.